par Pixmaker | Jan 23, 2025 | Non classé
Eukarÿs and Genethon have announced a strategic partnership to reduce the cost of gene therapy drugs production. By combining Eukarÿs’ innovative disruptive C3P3 technology, which enhances unleashes mRNA synthesis in mammalian cells, with Genethon’s...
par Pixmaker | Avr 16, 2024 | Non classé
Eukarÿs is pleased to announce the strengthening of its Board of Directors alongside the appointment of Guillaume Prunier as CEO. Gabriel Festoc, PhD, former President of Polyplus (acquired by Sartorius in 2023 for €2.4 billion), is a leading expert in bioproduction...
par Pixmaker | Mar 2, 2024 | Non classé
We are pleased to announce the publication of Eukarÿs’ latest research in Nature – Scientific Reports. The paper, entitled « Rational Design of an Artificial Tethered Enzyme for Non-Templated Post-Transcriptional mRNA Polyadenylation by the Second...
par Pixmaker | Mar 1, 2024 | Non classé
Eukarÿs is pleased to announce the appointment of Guillaume Prunier as its new Chief Executive Officer, effective March 1st 2024. A serial entrepreneur with expertise in DeepTech innovation, Guillaume previously served as CEO of Flaminem, a big data and AI startup...
par Pixmaker | Août 3, 2021 | Non classé
The third patent family builds on the previous two and provides a highly significant boost to the efficacy of the C3P3 enzyme. Filed in 2021, it protects the innovative concept of C3P3-G3, which inhibits the critical phosphorylation of subunit A of the translation...
par Pixmaker | Oct 24, 2019 | Non classé
Eukarÿs is proud to announce that it has won the prestigious US Prix Galien MedStartUp 2019 for ‘Best collaboration with the pharmaceutical or biotechnology industry’. The award was presented on October 24 at the Alexandria Life Sciences Center in New...
